Effect of Treatment of Pre-induction Hypertension on Hemodynamic Stability During Induction of General Anesthesia

• Status: Not yet recruiting
• Trial end date: 2025-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if treatment of pre-induction hypertension with an intravenous short acting calcium channel antagonist will (1) reduce the magnitude and duration of blood pressure excursions outside of a pre-established normal range and (2) decrease the requirement for vasoactive medications during the period from induction of anesthesia until just prior to surgical incision.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Diego
• Treatments: Clevidipine

Criteria

Inclusion Criteria:

1. Provision of signed and dated informed consent form

2. Stated willingness to comply with all study procedures and availability for the duration of the study

3. Any patient older than 18 years

4. Scheduled for elective surgery requiring general anesthesia

5. Presenting with hypertension during the pre-operative assessment (defined as either a systolic blood pressure > 140 mmHg or a diastolic blood pressure > 90 mmHg

Exclusion Criteria:

1. Known adverse reaction to clevidipine or any of its constituent parts.

2. Presence of structural heart disease.

3. Known acute or chronic kidney disease.

4. Pregnancy or lactation.

5. Non-elective surgery.

6. Treatment with another investigational drug or other intervention at the time of enrollment.

7. Patients unable to consent for themselves.

8. Incarcerated patients.

9. Known defect in lipid metabolism.